For many years, cancer researchers focused on the attributes of tumour cells that lead to life-threatening malignancy. These studies have provided a comprehensive understanding of the role of oncogenes and tumour suppressor genes, as well as their associated signal transduction pathways, in cancer
. In [2] .
It has become clear that the non-cancerous cells that comprise the TME are not innocent bystanders; rather, they are conscripted to promote tumour progression. The TME contains multiple types of immune cells, which are recruited or activated by the chemokines and cytokines that are secreted by tumour cells [3] . In addition, cell death and necrosis drive the recruitment and activation of macrophages in the TME. Tumour-associated macrophages are a rich source of pro-angiogenic factors and they have been shown to promote metastasis [4, 5] . Various types of immune cells also facilitate tumour cell intravasion and promote the formation of premetastatic niches [6] . Cancer-associated fibroblasts (CAFs) also promote primary tumour growth and metastasis [7] [8] [9] . Multiple origins of CAFs have been proposed, including adjacent tissue, the bone marrow and endothelial cells [10, 11] . These cells express markers that are associated with an activated phenotype, such as stromal cell-derived factor-1 (SDF-1), fibroblast activation protein and ␣-smooth muscle actin [7] [8] [9] .
Vascular and lymphatic endothelial cells are recruited to the TME by the members of the VEGF family that are secreted by tumour and stromal cells [12] . In 1975, Judah Folkman proposed that tumours cannot grow beyond a relatively small size without stimulating a vascular system to supply them with nutrients [13] . [14] . This switch corresponds to the transition of a poorly vascularized tumour to one that is well vascularized. Thus, the presence of endogenous inhibitors of angiogenesis in the TME is probably central to tumour dormancy [15] . Of the endogenous inhibitors, thrombospondin-1 (TSP-1) is highly expressed in the TME by stromal fibroblasts and immune cells [16] . The importance of TSP-1 is underscored by the fact that oncogenes suppress TSP-1, whereas tumour suppressor genes stimulate TSP-1 [17, 18] 
Subsequent studies have validated this hypothesis and have identified key stimulators and inhibitors of angiogenesis. The data indicate that the relative concentrations of the stimulators and inhibitors determine endothelial cell phenotype, with the change from a quiescent to angiogenic phenotype being referred to as the 'angiogenic switch'

. Tumour cells have also been reported to instruct stromal cells to decrease their expression of TSP-1, thus, further decreasing the local barriers to angiogenesis [19]. This type of cross-talk between the tumour cells and stromal cells may facilitate co-evolution of the various cell types that comprise tumour tissue.
The ECM is a key component of the TME that has both positive and negative effects on tumour growth. Many of the endogenous inhibitors of angiogenesis are derived from ECM proteins [20] . However, the components of the ECM, including its associated growth factors and the cellular proteases that modify structure and function of the ECM, also promote tumour growth and metastasis [21] [22] [23] . Through its interaction with integrins, proteoglycans and other receptors, the ECM serves to support cytoskeletal organization, and cell adhesion, migration and invasion [24, 25] .
Taken [26] .
